Cargando…

Visceral Leishmaniasis in 2 Patients Treated With Lenalidomide and Dexamethasone: A Possible Correlation With Blunted Immune Response

Detalles Bibliográficos
Autores principales:	Hadjiaggelidou, Christina, Vadikolia, Chrysanthi, Verrou, Evgenia, Yiannaki, Efthalia, Triantafyllou, Theodora, Palaska, Vasiliki, Keramidioti, Konstantina, Tsirou, Kyriaki, Papanikolaou, Asimina, Markala, Dimitra, Konstantinidou, Pavlina, Katodritou, Eirini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732337/ https://www.ncbi.nlm.nih.gov/pubmed/33324952 http://dx.doi.org/10.1097/HS9.0000000000000506

Ejemplares similares

Chronic myelogenous leukemia occurring in two brothers: The opposite sides of the same coin?
por: Verrou, Evgenia, et al.
Publicado: (2021)

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
por: Katodritou, Eirini, et al.
Publicado: (2018)

Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment
por: Hadjiaggelidou, Christina, et al.
Publicado: (2021)

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.
por: Katodritou, Eirini, et al.
Publicado: (2023)

Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation
por: Gavriilaki, Eleni, et al.
Publicado: (2020)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
por: Leleu, Xavier, et al.
Publicado: (2022)

P920: EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE.
por: Katodritou, Eirini, et al.
Publicado: (2023)

P916: COEXISTENCE OF ≥2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE GREEK MYELOMA STUDY GROUP
por: Katodritou, E., et al.
Publicado: (2022)

Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

Clinical characteristics in patients with non-cardiac chest pain could favor gastroesophageal reflux disease diagnosis
por: Karlaftis, Anastasios, et al.
Publicado: (2013)

Yield of Combined Impedance-pH Monitoring for Refractory Reflux Symptoms in Clinical Practice
por: Karamanolis, Georgios, et al.
Publicado: (2011)

Epithelial morphogenesis in the Drosophila egg chamber requires Parvin and ILK
por: Keramidioti, Athina, et al.
Publicado: (2022)

Bravo 48-hour Wireless pH Monitoring in Patients With Non-cardiac Chest Pain. Objective Gastroesophageal Reflux Disease Parameters Predict the Responses to Proton Pump Inhibitors
por: Karamanolis, Georgios, et al.
Publicado: (2012)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Lenalidomide-Associated ITP
por: Herold, Christina I., et al.
Publicado: (2011)

EUS in the management of gastric cancer
por: Papanikolaou, Ioannis S., et al.
Publicado: (2011)

Total Antioxidant Capacity, Haematological and Coagulation Parameters after Orthodox Christian Fast
por: Makedou, Kali G., et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Hyperbilirubinemia following lenalidomide administration
por: Azmy, Veronica, et al.
Publicado: (2018)

Lenalidomide‐induced eosinophilic pneumonia
por: Toma, Andrew, et al.
Publicado: (2017)

Therapy of Angiosarcoma with Thalidomide and Lenalidomide
por: Mattes, M. Jules, et al.
Publicado: (2021)

Severe Lenalidomide-Associated Hyperbilirubinemia
por: Gildea, Daniel T, et al.
Publicado: (2023)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Commentary: Long-term Practice with Domain-Specific Task Constraints Influences Perceptual Skills
por: Yiannaki, Christopher, et al.
Publicado: (2018)

Successful Control of Acute Myelofibrosis with Lenalidomide
por: Vassilopoulos, G., et al.
Publicado: (2010)

Mechanism of action of lenalidomide in hematological malignancies
por: Kotla, Venumadhav, et al.
Publicado: (2009)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
por: Cortelezzi, Agostino, et al.
Publicado: (2012)

Novel insights into the mechanism of action of lenalidomide
por: Semeraro, Michaela, et al.
Publicado: (2014)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Lenalidomide-induced diffuse alveolar hemorrhage
por: Saheer, S., et al.
Publicado: (2014)

Expanding role of lenalidomide in hematologic malignancies
por: Ghosh, Nilanjan, et al.
Publicado: (2015)

Reversible Fanconi syndrome due to lenalidomide
por: Glezerman, Ilya G., et al.
Publicado: (2008)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Optimized Sedation Improves Colonoscopy Quality Long-Term
por: Triantafyllou, Konstantinos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_oo7mcpslasf1pelsntig4al2om